UPM Pharmaceuticals successfully serialized their first product in May of this year. UPM anticipates having all of their clients' products serialized by November 2017.
In accordance with the Drug Supply Chain Security Act which had mandated that pharmaceutical manufacturers serialize all pharmaceutical products starting in November 2017, UPM is excited to be ahead of schedule. All products will be serialized by the FDA’s extended deadline of November 2018, if not before.
UPM has chosen Laetus as its serialization hardware platform. Lateus has over 40 years of experience in the development and production of inspection solutions, UPM was confident in the decision to proceed with Laetus to ensure serialization accuracy and product quality. In November of 2016, three members of the UPM staff attended Laetus ‘Track and Trace Academy’ for 5 days in Bensheim, Germany for individualized training sessions with a high level of practical content.
CEO of UPM Pharmaceuticals, Jim Gregory states, "While we know the FDA recently granted a one year extension on their serialization deadline, we are very excited about our early implementation and success with serialization. Using the Lateus system provides 100% verification of the data matrix code against the human readable text. This insures products leaving the UPM facility are fully compliant and traceable. Lateus equipment also allowed us flexibility in that everything is printed in our label office and can be printed in advance. This saves time and the client money."
UPM is using TraceLink as their code provider. TraceLink is the World’s Largest Track and Trace Network for connecting the supply chain and eliminating counterfeiting of prescription medication around the world. TraceLink allows companies to focus on one Track and Trace solution world wide.
About UPM Pharmaceuticals
UPM Pharmaceuticals, Inc. is an independent drug development and contract manufacturer serving the pharmaceutical and biotechnology industries. We provide high quality drug development services including custom formulation development, cGMP clinical and commercial manufacturing, analytical methods services, and stability testing. UPM’s clients enjoy service that is customized and fast with total quality management characteristics of a customer focused business. Our history includes successful collaborative interactions with small virtual and large billion dollar companies providing customized product development services and solutions. UPM focuses on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets, and semi-solid creams and ointments. Our 475,000 square foot commercial manufacturing facility based in Bristol, Tennessee allows us to serve our clients’ needs from early stage development to large scale commercial production.
Contact
Mary Lee Schiesz
Manager of Marketing
Email: mschiesz@upm-inc.com
Phone: +1 (423) 989-7057
